The Clinical Data Dilemma: Balancing Speed and Credibility in Communicating Early-Stage Life Science Clinical Results

Prepared by Putnam Insights LLC

For any early-stage bio- or med-tech company, the arrival of initial positive clinical data presents an immediate dual challenge.

First, there is the fundamental need to establish a highly credible, enduring platform for your science. To gain traction with medical opinion leaders and regulatory bodies, the data must eventually live in a respected, peer-reviewed medical journal.

Second, there is the relentless clock of the private markets. You need to communicate these clinical results with a sense of genuine urgency to current investors, prospective financial backers, and potential strategic partners.

Historically, these two needs directly opposed one another. The gold standard of peer review takes months—often quarters—which fundamentally misaligns with the runway and fundraising cycles of a pre-revenue life sciences company. Releasing the data too broadly via a corporate press release risked violating the traditional rules of medical publishing, guaranteeing an automatic rejection from top-tier journals for prior publication.

Today, there is a powerful bridge: the medical preprint server.

The "Ingelfinger Rule" and Journal Policies: Will They Reject You?

Historically, medical journals operated under the Ingelfinger Rule—a policy established in the 1960s by Franz Ingelfinger (then editor of the New England Journal of Medicine), which stated that a journal would automatically reject any manuscript if its data had been published elsewhere first.

Today, the Ingelfinger Rule is largely dead regarding pre-prints.

The vast majority of top-tier medical journals have updated their policies to state that posting a manuscript on a recognized, non-profit pre-print server does not constitute prior publication.

The Most Prominent Medical Pre-Print Servers

The medical and life sciences ecosystem relies on several highly trusted, non-profit platforms, including these three as the most prominent:

• medRxiv (pronounced "med-archive"): Launched in 2019 by Cold Spring Harbor Laboratory, BMJ, and Yale University, this is the gold standard for clinical research. It hosts manuscripts covering clinical trials, epidemiology, and health economics.
• bioRxiv: The older sibling to medRxiv (also run by Cold Spring Harbor), focused on basic biology, preclinical models, and laboratory life sciences.
• SSRN (specifically "Preprints with The Lancet"): Owned by Elsevier, SSRN hosts various research networks. It has a formal collaboration where papers submitted to The Lancet family can be automatically opted into their dedicated preprint space.
• TechRxiv: Focused on biomedical engineering, medical hardware, wearables, and healthcare AI, this is operated by the Institute of Electrical and Electronics Engineers (IEEE), and is the premier server for the engineering validation of med-tech.

The Strategic Value of Platforms Like medRxiv

Pre-print archive servers like those named above have fundamentally altered the timeline of medical publishing. Major organizations, including the International Committee of Medical Journal Editors (ICMJE), now recognize preprints as legitimate components of the publishing ecosystem.

When you upload a manuscript to a recognized non-profit preprint server, it undergoes a rapid screening process to check for plagiarism and basic ethical compliance, and is typically posted within 48 hours. The manuscript receives a permanent Digital Object Identifier (DOI), making it a permanent, citable record.

Most importantly, the vast majority of top-tier medical journals—including NEJM, JAMA, and The Lancet—have updated their policies to state clearly that posting to a recognized preprint server does not constitute prior publication. You preserve your pathway to high-impact peer review while making your data immediately accessible.

The Catch: How You Communicate Determines Your Fate

While the journals have embraced preprints, they remain fiercely protective of their embargoes and their role in validating science for the broader public.

If you use a preprint server, your communication strategy must shift from a traditional "big splash" PR campaign to a highly disciplined, multi-tiered approach.

Tier 1: Targeted Corporate and Investor Engagement (Immediate)

Once the manuscript is live on a preprint server, it is public domain. You can use it immediately to drive corporate objectives, provided you do so within the bounds of scientific decorum:

• Investor Relations: You can seamlessly integrate the preprint DOI into your investor decks and data rooms. It provides an immediate, verifiable link to your complete methodology and results, rather than asking investors to rely solely on a sanitized corporate summary.
• Partner and KOL Outreach: You can legally and openly share the manuscript with prospective clinical and strategic partners to advance business development conversations.
• The Guardrail: In every investor deck or KOL communication, the data must be explicitly labeled as "Pre-print: Ahead of formal peer review." 

Tier 2 (Optional): The Pre-Print Corporate Press Release (Immediate)

This is where early-stage companies can make fatal errors. Even though the preprint is public, one must not actively promote it to the lay media.

• Do not pitch mainstream healthcare or lay reporters.
• Do not hold a press conference.

If a corporate press release is issued immediately upon the medRxiv or other pre-print archive posting (to support a concurrent fundraising announcement, or required for material compliance), it must be drafted defensively:

• Mandatory Disclaimer Front-and-Center: The press release must include an explicit notice mirroring medRxiv's own warning. For example: "This research is a preprint and has not yet been certified by peer review. It reports new medical research that has yet to be evaluated by the medical community and should not be used to guide clinical practice."
• Focus on the Milestone, Not Just the Data: The headline should focus on the fact that the data has been submitted for review or compiled for scientific community evaluation, rather than proclaiming clinical victory.
• Omit Direct Clinical Advice or Consumer Judgments: Keep the language dense, scientific, and corporate. The moment a release reads like marketing copy directed at patients, editors at top journals take notice.

Tier 3: The Formal Press Embargo (Deferred to Journal Acceptance)

Save the mainstream, widespread media push for the peer-reviewed publication date.

• When the paper is eventually accepted by a journal, the publisher will set a strict Journal Embargo Lift Date and Time.
• During the week leading up to that date, your PR team can distribute the final, accepted manuscript and a corporate press release to accredited journalists under a strict embargo. This gives reporters time to interview your executive team and write accurate stories that break the exact moment the journal publishes the peer-reviewed version.
• You will supplement the embargo reach-out with active pitching and promotion to media concurrent with the embargo lift date and time.

The Takeaway

For pre-revenue companies engaged in fundraising and strategic partnering, waiting six to twelve months for peer review is no longer a requirement to validate your clinical progress. Medical preprints offer a highly credible, rapid-deployment mechanism to share data with the stakeholders who matter most right now.

By treating the preprint as an immediate tool for investors and partners—while strictly reserving broad media outreach for final journal publication—you can satisfy the urgent demands of the capital markets without sacrificing the enduring credibility of the medical establishment.

#PutnamInsights